vs

Side-by-side financial comparison of Cardio Diagnostics Holdings, Inc. (CDIO) and IMMUCELL CORP (ICCC). Click either name above to swap in a different company.

IMMUCELL CORP is the larger business by last-quarter revenue ($5.5M vs $3.6K, roughly 1548.8× Cardio Diagnostics Holdings, Inc.). On growth, IMMUCELL CORP posted the faster year-over-year revenue change (-8.4% vs -21.2%). IMMUCELL CORP produced more free cash flow last quarter ($-1.8M vs $-5.9M). Over the past eight quarters, IMMUCELL CORP's revenue compounded faster (3.9% CAGR vs -52.8%).

Cardio Diagnostics Holdings, Inc. is a precision cardiovascular healthcare company that develops and commercializes integrated genetic and epigenetic diagnostic tests for early detection of coronary heart disease, heart failure, and other cardiovascular conditions. It primarily serves healthcare providers, clinical laboratories, and patients across the United States, focusing on delivering accessible, personalized cardiovascular care solutions.

ImmuCell Corp is a US-based animal health biotechnology company that develops, manufactures and markets innovative products for livestock, primarily dairy cattle. Its core offerings include preventive and therapeutic solutions for common bovine health issues such as mastitis, serving agricultural producers and veterinary providers across North America.

CDIO vs ICCC — Head-to-Head

Bigger by revenue
ICCC
ICCC
1548.8× larger
ICCC
$5.5M
$3.6K
CDIO
Growing faster (revenue YoY)
ICCC
ICCC
+12.8% gap
ICCC
-8.4%
-21.2%
CDIO
More free cash flow
ICCC
ICCC
$4.1M more FCF
ICCC
$-1.8M
$-5.9M
CDIO
Faster 2-yr revenue CAGR
ICCC
ICCC
Annualised
ICCC
3.9%
-52.8%
CDIO

Income Statement — Q4 2025 vs Q3 2025

Metric
CDIO
CDIO
ICCC
ICCC
Revenue
$3.6K
$5.5M
Net Profit
$-139.7K
Gross Margin
42.9%
Operating Margin
0.4%
Net Margin
-2.5%
Revenue YoY
-21.2%
-8.4%
Net Profit YoY
3.6%
80.1%
EPS (diluted)
$-0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CDIO
CDIO
ICCC
ICCC
Q4 25
$3.6K
Q3 25
$2.9K
$5.5M
Q2 25
$7.5K
$6.4M
Q1 25
$940
$8.1M
Q4 24
$4.5K
$7.8M
Q3 24
$6.6K
$6.0M
Q2 24
$7.9K
$5.5M
Q1 24
$15.9K
$7.3M
Net Profit
CDIO
CDIO
ICCC
ICCC
Q4 25
Q3 25
$-1.7M
$-139.7K
Q2 25
$-1.7M
$501.9K
Q1 25
$-1.6M
$1.4M
Q4 24
Q3 24
$-1.4M
$-701.7K
Q2 24
$-1.3M
$-1.5M
Q1 24
$-4.2M
$-437.9K
Gross Margin
CDIO
CDIO
ICCC
ICCC
Q4 25
Q3 25
42.9%
Q2 25
43.7%
Q1 25
41.6%
Q4 24
36.5%
Q3 24
26.3%
Q2 24
22.5%
Q1 24
31.6%
Operating Margin
CDIO
CDIO
ICCC
ICCC
Q4 25
Q3 25
-59950.9%
0.4%
Q2 25
-22457.5%
8.8%
Q1 25
-173463.8%
13.9%
Q4 24
8.0%
Q3 24
-21412.9%
-9.6%
Q2 24
-16295.6%
-25.3%
Q1 24
-26105.3%
-4.1%
Net Margin
CDIO
CDIO
ICCC
ICCC
Q4 25
Q3 25
-60053.8%
-2.5%
Q2 25
-22517.7%
7.8%
Q1 25
-173943.0%
17.9%
Q4 24
Q3 24
-21467.6%
-11.7%
Q2 24
-16365.9%
-28.0%
Q1 24
-26140.0%
-6.0%
EPS (diluted)
CDIO
CDIO
ICCC
ICCC
Q4 25
Q3 25
$-0.98
$-0.02
Q2 25
$-0.97
$0.06
Q1 25
$-0.97
$0.16
Q4 24
$0.09
Q3 24
$-1.73
$-0.09
Q2 24
$-1.71
$-0.20
Q1 24
$-5.93
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CDIO
CDIO
ICCC
ICCC
Cash + ST InvestmentsLiquidity on hand
$3.9M
Total DebtLower is stronger
$9.5M
Stockholders' EquityBook value
$7.0M
$29.8M
Total Assets
$7.8M
$45.7M
Debt / EquityLower = less leverage
0.32×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CDIO
CDIO
ICCC
ICCC
Q4 25
Q3 25
$3.9M
Q2 25
Q1 25
Q4 24
$3.8M
Q3 24
Q2 24
$1.3M
Q1 24
$960.3K
Total Debt
CDIO
CDIO
ICCC
ICCC
Q4 25
Q3 25
$9.5M
Q2 25
Q1 25
$8.7M
Q4 24
$9.0M
Q3 24
$9.4M
Q2 24
$9.8M
Q1 24
$10.2M
Stockholders' Equity
CDIO
CDIO
ICCC
ICCC
Q4 25
$7.0M
Q3 25
$8.2M
$29.8M
Q2 25
$9.7M
$29.9M
Q1 25
$11.4M
$29.0M
Q4 24
$9.6M
$27.5M
Q3 24
$3.7M
$26.4M
Q2 24
$3.1M
$23.5M
Q1 24
$3.0M
$24.6M
Total Assets
CDIO
CDIO
ICCC
ICCC
Q4 25
$7.8M
Q3 25
$8.8M
$45.7M
Q2 25
$10.4M
$46.7M
Q1 25
$12.3M
$45.6M
Q4 24
$10.6M
$45.1M
Q3 24
$4.5M
$44.4M
Q2 24
$4.0M
$41.9M
Q1 24
$4.3M
$43.1M
Debt / Equity
CDIO
CDIO
ICCC
ICCC
Q4 25
Q3 25
0.32×
Q2 25
Q1 25
0.30×
Q4 24
0.33×
Q3 24
0.36×
Q2 24
0.42×
Q1 24
0.41×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CDIO
CDIO
ICCC
ICCC
Operating Cash FlowLast quarter
$-5.7M
$-1.2M
Free Cash FlowOCF − Capex
$-5.9M
$-1.8M
FCF MarginFCF / Revenue
-166361.5%
-32.3%
Capex IntensityCapex / Revenue
5269.1%
10.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-10.5M
$715.4K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CDIO
CDIO
ICCC
ICCC
Q4 25
$-5.7M
Q3 25
$-1.4M
$-1.2M
Q2 25
$-1.6M
$1.6M
Q1 25
$-1.4M
$1.6M
Q4 24
$-5.0M
$-3.1K
Q3 24
$-1.2M
$-639.3K
Q2 24
$-1.2M
$581.8K
Q1 24
$-1.2M
$418.5K
Free Cash Flow
CDIO
CDIO
ICCC
ICCC
Q4 25
$-5.9M
Q3 25
$-1.6M
$-1.8M
Q2 25
$-1.6M
$1.4M
Q1 25
$-1.4M
$1.2M
Q4 24
$-5.2M
$-199.3K
Q3 24
$-1.2M
$-727.7K
Q2 24
$-1.4M
$471.0K
Q1 24
$-1.3M
$348.1K
FCF Margin
CDIO
CDIO
ICCC
ICCC
Q4 25
-166361.5%
Q3 25
-54509.7%
-32.3%
Q2 25
-21273.1%
22.4%
Q1 25
-149562.6%
15.4%
Q4 24
-115422.6%
-2.6%
Q3 24
-17942.3%
-12.1%
Q2 24
-17513.3%
8.6%
Q1 24
-7866.9%
4.8%
Capex Intensity
CDIO
CDIO
ICCC
ICCC
Q4 25
5269.1%
Q3 25
5703.5%
10.8%
Q2 25
250.1%
2.4%
Q1 25
615.6%
4.1%
Q4 24
4759.9%
2.5%
Q3 24
353.3%
1.5%
Q2 24
2133.4%
2.0%
Q1 24
125.5%
1.0%
Cash Conversion
CDIO
CDIO
ICCC
ICCC
Q4 25
Q3 25
Q2 25
3.19×
Q1 25
1.09×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons